BMI View: Multinational drugmaker presence in Botswana will be limited to imports as the small market
size and lack of investment incentives deter any large-scale investment plans. Although generic drugs will
retain their dominance in terms of market share, as the burden of non-communicable diseases increases this
will create more lucrative opportunities for foreign drugmakers. The government will...
BMI View: The Zambian government will continue to boost social expenditure as President Lungu attempts
to gain public favour in light of the August general elections. Fiscal revenues will increase gradually, in
line with the copper sector’s slow recovery, but real GDP growth in Zambia will still remain subdued in
2016. Government expenditure maintains a focus on unproductive areas of the economy,...
BMI View: Leveraging Vietnam’s National Expanded Immunisation Programme (EPI) will be of strategic
benefit to multinational pharmaceutical firms with a strong vaccines portfolio. Government support for the
initiative is expected to remain strong, which bodes well for firms as the EPI alleviates financial barriers
that might dissuade patients from receiving treatment. A key risk to this approach...